Objective To assess whether inhaled nitric oxide (iNO) improves survival without bronchopulmonary dysplasia (BPD) for preterm African American infants.
B
ronchopulmonary dysplasia (BPD) in preterm infants (<34 weeks of gestation) remains a highly significant and costly cause of mortality and morbidity. 1 Based on preclinical studies in a variety of animal models, [2] [3] [4] [5] [6] [7] [8] there is evidence that inhaled nitric oxide (iNO) may prevent some of the developmental changes leading to BPD. A number of clinical trials of iNO to prevent BPD in preterm infants have been conducted, with varied results. 9 Schreiber et al demonstrated improved survival without BPD. 10 In this trial, intubated infants were started on 10 parts per million (ppm) of iNO for 7 days and the enrolled cohort was 70% African American. In the Nitric Oxide to prevent Chronic Lung Disease (NOCLD) trial, infants had a higher exposure to iNO (starting at 20 ppm, tapered over 24 days) than in other trials. 11 In addition, African American and Hispanic infants had better survival without BPD than other races (P = .055 for interaction between race and treatment).
In 2011, the Meta-analysis of Preterm Patients on Inhaled Nitric Oxide (MAPPiNO) Collaboration was formed to further explore the variation in outcomes from the various trials by undertaking an individual participant data (IPD) meta-analysis of 12 trials meeting prespecified inclusion criteria. 12 Some of the advantages of IPD meta-analysis over meta-analysis based on aggregate data include improved uniformity in defining participant characteristics and outcome measures, including subgroup definitions, the ability to adjust for the nonindependence of siblings within the dataset, and the opportunity to collect information on longer term outcomes. 13 The objectives of the MAPPiNO IPD meta-analysis were to determine whether iNO treatment in preterm infants receiving assisted ventilation improved survival rates with less BPD, and whether the outcome of trials differed according to participant-or intervention-related factors, including gestational age at birth, birth weight, multiplicity, race, postnatal age at the time of randomization, iNO dosage and duration of administration, as well as other comorbidities of prematurity. In MAPPiNO, one of the prespecified subgroup analyses was a starting iNO dose categorized as 5 ppm or less, or greater than 5 ppm, by trial design. , respectively; P = .02 for interaction). The trials starting with an iNO dose of greater than 5 ppm, all had an intention to treat infants for a minimum of 7 days providing a greater overall exposure to iNO for infants in those trials. A further prespecified subgroup analysis of the MAPPiNO IPD meta-analysis was the effect of race, which showed a trend toward greater treatment effect in non-White infants compared with Whites, but which was not statistically significant. 14 The 2010 National Institutes of Health Consensus Conference on the use of iNO in the preterm infants 15 concluded that, although there was insufficient evidence to recommend the routine use of iNO to prevent CLD, "the positive results from one multicenter trial, 11 characterized by later timing, higher dose and longer duration require confirmation." This recommendation, in addition to the publication of the MAPPiNO results, led to an additional randomized trial assessing the effect of iNO in preterm infants, the NEWborns treated with inhaled Nitric Oxide (NEWNO) trial, 16 which used the longer, higher dose regimen, similar to the NOCLD trial. Although there was a baseline imbalance in enrollment by race (White 52% of iNOtreated infants vs 38% of controls) in this trial, there was a trend toward better survival without BPD in African American infants (45% in iNO group vs 35% in placebo group; P = .213) but not in Whites. To further analyze these observations from 3 trials, 10, 11, 16 and the MAPPINO analysis 12 related to iNO dose and race, we performed an IPD meta-analysis, named the Race and inhaled Nitric Oxide in Preterm Infants (RiNOP) study.
BPD

Methods
Studies were considered eligible for this IPD meta-analysis if they had randomly assigned preterm infants born at less than 34 weeks of gestation who were receiving respiratory support, to either iNO or a placebo. The studies also fulfilled the following criteria: they enrolled at least 50 infants and remained blinded to treatment allocation; a minimum of 15% of the enrolled infants or at least 10 infants in each treatment arm were of African American race, selected to allow for a sufficient number of African American infants for analysis; the trial protocol started infants on greater than 5 ppm of iNO with the intention to treat infants for at least 7 days; and the investigators had IPD available to be analyzed. All of the eligible individual studies had ethics committee/institutional review board approval and parental consent. The investigators of each eligible trial were contacted and invited to join the collaborative group and to supply line-by-line raw data for each individual, randomly assigned participant in their trial. These data were then checked for any missing information, errors, or inconsistency with previously published reports. The main outcomes were calculated for each participant to align with the prespecified definitions as outlined in the eligible trial protocols. All randomized participants with outcome data available were included in the analyses, which were performed on an intention-to-treat basis.
For each of the outcomes, a 1-stage approach to analysis was undertaken so that the IPD from the eligible trials were included in a single model. This enabled the variation across trials to be accounted for within the model by including a fixed trial effect. For binary outcomes, RRs and 95% CIs were obtained using log-binomial regression models and for continuous variables mean differences and 95% CIs between treatment groups were obtained using linear regression models. A treatmentby-trial interaction term was tested for each outcome to assess the heterogeneity of treatment effect across trials. 17 Models assessing whether race is predictive of treatment benefit included a test for interaction between race and treatment and were adjusted for trial. Because multiple births occurred frequently (17%) in the eligible trials, correlation between outcomes owing to multiple births was taken into account using generalized estimating equations. 18 The primary endpoint of this IPD meta-analysis was a composite outcome of death or BPD, defined as requiring respiratory support or supplemental oxygen at 36 weeks' postmenstrual age. Schreiber also used chest radiographs as part of the BPD definition, and both the NOCLD and NEWNO trials used the oxygen reduction test to determine the need for supplemental oxygen. Secondary endpoints included death before discharge, postnatal steroid use, gross pulmonary air leak, pulmonary hemorrhage, measures of respiratory support, and duration of hospital stay. Subgroup analyses for all endpoints were performed by race/ ethnicity category (defined as either non-Hispanic African American race, non-Hispanic white race, Hispanic ethnicity, other race, or unknown) to evaluate the effect of maternal selfreported race on outcome. All statistical analyses were performed in SAS 9.4 (SAS Institute, Cary, North Carolina) and were not adjusted for multiple testing.
Results
There were 3 trials that met the prespecified criteria for inclusion in the IPD with outcome data available for 1240 preterm infants. Schreiber 10 and NOCLD 11 were the 2 trials included in the original MAPPiNO IPD meta-analysis that started with greater than 5 ppm iNO by protocol. A third trial, the NEWNO trial, 16 which was conducted subsequent to the MAPPiNO publication, also met the criteria (Figure 1 ; available at www.jpeds.com) and the IPD were made available to the data management team at the National Health and Medical Research Council Clinical Trials Centre at the University of Sydney by IKARIA INC, the sponsoring organization. Table I presents the key protocol specifications of the included trials. The NOCLD trial used iNO starting at 20 ppm for 4 days, then decreasing to 10, 5, and 2 ppm at weekly intervals. NEWNO used a similar schedule, but remained at 5 ppm until 24 days. The Schreiber trial started at 10 ppm and decreased to 5 ppm with an intention to treat for at least 7 days. Figure 2 lists the main outcomes by race/ethnicity. Compared with infants of other races, African American infants had a significant reduction in the composite outcome of death or BPD with iNO treatment: 49% in the iNO treated infants compared with 63% in the control infants (RR, 0.77; 95% CI, 0.65-0.91; P = .003), with an interaction P value of .016. In the placebo group, there was no difference in death or BPD by race for these high-risk ventilated preterm infants. There was no difference in the response to iNO for infants entered into the trials of White (P = .87), Hispanic (P = .14), or other maternal self-reported races/ethnicities (P = .21). There was no difference between racial groups for death at any time, death at discharge, or death at 36 weeks. There was, however, a significant difference between races (interaction P = .023) for the effect of iNO treatment on the incidence of BPD in survivors, with the greatest effect being seen in African American infants (P = .005). There was no difference between racial groups in use of postnatal steroids or for incidence of pulmonary air leak or pulmonary hemorrhage (data not shown).
Table IV presents outcomes for all infants by treatment using an IPD meta-analysis of participants in the 3 trials of high iNO exposure included in this study. Overall, the composite outcome of death or BPD was reduced in infants treated with iNO (58%) vs control infants (65%; RR, 0.90; 95% CI, 0.82-0.98; P = .018). There was no difference in death at any time point between the 2 treatment groups. Meta-analyzed data from the 3 included trials also showed a statistically significant reduction in BPD for surviving infants treated with iNO (RR, 0.89; 95% CI, 0.80-0.98; P = .02). None of the prespecified continuous outcomes, including measures of respiratory support and hospital stay, showed significant differences for iNO-treated compared with placebo infants, nor were there any differences by race (Tables V and VI; available at www.jpeds.com).
Discussion
The results of this IPD meta-analysis revealed that there was no respiratory benefit at 36 weeks' postmenstrual age for infants whose maternal self-reported race was White, Hispanic, or Multiples in trial, n (%) 26 (13) 84 (14) 103 (30) CLD, Chronic lung disease; CPAP, continuous positive airway pressure; CXR, chest radiographs; RCT, randomized controlled trial; RDS, respiratory distress syndrome. classified as other and who were treated with iNO starting at a dose of greater than 5 ppm. However, treated African American infants in the 3 trials included in this meta-analysis had a statistically significant benefit from iNO treatment, with a number needed to treat of 7. Between racial groups there were no imbalances in other factors that potentially influenced the death or BPD outcome (Table III) . We did not see a difference in duration of hospitalization or resource use in the meta-analysis, although there was a significant decrease noted in the NOCLD trial. 19 Of note, African American race was not associated with fewer deaths or less BPD in the placebo group, indicating a similar risk for untreated infants, regardless of race. Thus, the apparent benefit of iNO for all infants in these trials is largely derived from a significant treatment response in African American infants.
There are a number of reported observations supporting racial disparity in the production, metabolism, and/or function of Nitric Oxide (NO). Black or Asian maternal race compared with white race is associated independently with persistent pulmonary hypertension of the newborn, a disease that is likely related to endogenous NO signaling and that is responsive to iNO therapy. 20 Several studies indicate reduced bioavailability of NO in African Americans compared with Whites, likely in part due to increased oxidation of NO. In laboratory studies, release of NO from umbilical venous endothelial cells has been shown to be substantially less for African Americans compared with White infants. 21, 22 Levels of urinary NO metabolites are higher in self-reported White compared with African American and Hispanic premature infants, both with and without iNO treatment, perhaps reflecting differences in NO metabolism and, thus, bioavailability. 23 In adults, African Americans have increased frequency of hypertension and cardiovascular disease, and a NO-targeted medication (hydralazine hydrochloride and isosorbide dinitrate) is an indicated therapy for heart failure specifically in African Americans. [23] [24] [25] It is likely that these racial differences in NO bioavailability and response are due to genetic variation in key genes on NO pathways, and both racial and ethnic differences exist for allele frequency of single nucleotide polymorphisms in many related genes, including NOS1 and NOS3. [26] [27] [28] [29] [30] Some limitations of the RiNOP study include that the era of enrollment for the trials was before 2011, so the results may not reflect recent advances in infant intensive care that could impact iNO response and respiratory outcome. In addition, there were small differences in the definition of BPD between studies. Race was assigned by maternal self-report and, thus, does not capture the proportion of African, European, and Native American ancestry within individuals. However, we have observed a high concordance between genetic African ancestry and self-reported African American race in the Trial Of Late SURFactant trial cohort (unpublished data). 31 One trial (Schreiber 2003) 10 was a single-center study, but the other two (NOCLD, NEWNO) 11, 16 were multicenter trials involving a total of 54 different sites. Despite the similarity between racial groups in gestational age (Table III) , it is possible that African American infants were more developmentally mature, as has been proposed based on population data for gestational age at delivery, 32 and that maturity impacts responsiveness to iNO. However, this was not observed in our analysis by gestational age (data not presented). Although the 3 trials included a reasonable number of African American infants, there were relatively few infants of other racial backgrounds and thus there was insufficient power to examine the efficacy of iNO in other racial groups. However, it is of particular interest that some Hispanic populations have a substantial proportion of African ancestry, which may also convey iNO responsiveness. 33 Another limitation of this study is the lack of longer term outcome data to analyze via IPD meta-analysis at 40 weeks' postmenstrual age or later in infancy. Although both the Schreiber and NOCLD trials reported improved longer term outcomes, 34, 35 there was no difference in either pulmonary or neurodevelopmental outcomes in treated vs control infants in the NEWNO study. 16 It is well-known that many other environmental and social factors influence the long-term outcome in these high-risk infants. A multicenter randomized trial targeting this population would provide further valuable information.
Our IPD meta-analysis of 3 randomized, controlled trials of iNO supports further investigation of genetic ancestry and the potential contribution of genetic variants related to NO and biological pathways leading to BPD. Because iNO is safe and well-tolerated by infants, and may reduce later respiratory morbidity 34 as well as BPD/death with a number needed to treat of 7, we suggest that iNO therapy should be considered for preterm African American infants at high risk for BPD. There was also a 9 percentage point reduction in the rate of BPD in survivors (46% iNO vs 55% placebo) in Hispanic infants (many of whom have some African ancestry) 31 that, although not statistically significant, may provide rationale for also considering therapy in this population. We conclude that iNO to prevent BPD in African Americans represents an example of a racially customized therapy for infants. ■ ETT, endotrachael tube; PMA, postmenstrual age.
